. 2021 May 28;10(11):2382. doi: 10.3390/jcm10112382

Table 1.

Basic statistics and comparison of studied protein concentrations measured in the plasma and amniotic fluid samples.

Marker	Material	Study Group	Unit	Median Value	Min	Max	p Value (Control vs. T21)	p Value (between Study Material)
Marker	Material	Study Group	Unit	Median Value	Min	Max	p Value (Control vs. T21)	Control PS vs. Control AF	T21 PS vs. T21 AF
25-OH vitamin D	PS	Control	mg/mL	22.22	14.00	35.92	NS	p < 0.01	NS
	PS	T21		19.51	14.24	30.44	NS
	AF	Control		30.60	14.24	51.34	NS
	AF	T21		25.20	12.59	42.07	NS
Asprosin	PS	Control	ng/mL	10.57	4.45	15.17	p < 0.0001	NS	NS
	PS	T21		17.28	12.94	26.59	p < 0.0001
	AF	Control		10.87	4.01	17.03	p < 0.0001
	AF	T21		15.53	8.09	24.77	p < 0.0001
AGE	PS	Control	ng/mL	12.96	4.96	26.03	p < 0.001	p < 0.01	p < 0.0001
	PS	T21		9.16	4.52	13.01	p < 0.001
	AF	Control		8.27	3.06	11.55	p < 0.0001
	AF	T21		3.00	1.67	4.89	p < 0.0001
IMA	PS	Control	µg/mL	6.79	5.00	12.00	p < 0.0001	p < 0.0001	NS
	PS	T21		3.61	0.90	22.52	p < 0.0001
	AF	Control		2.64	1.05	9.34	NS
	AF	T21		2.28	0.33	6.23	NS
A1AT	PS	Control	mg/L	1.98	0.95	3.38	NS	p < 0.001	p < 0.0001
	PS	T21		1.95	1.26	1.69	NS
	AF	Control		0.49	0.08	2.90	p < 0.0001
	AF	T21		0.18	0.01	0.56	p < 0.0001
DNA/RNA OSDP	PS	Control	pg/mL	37.81	23.21	46.83	NS	NS	NS
	PS	T21		37.57	28.53	58.40	NS
	AF	Control		31.16	12.64	45.22	p < 0.05
	AF	T21		38.48	27.06	51.46	p < 0.05

A1AT, alfa-1-antitrypsin; AF, amniotic fluid; AGE, advanced glycation end products; IMA, ischemia-modified albumin; NS, not significant; OSDP, oxidative stress damage product; PS, plasma; T21, trisomy 21.